A new oral weight loss pill shows results similar to Ozempic and Wegovy injections in the treatment of obesity.

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the ...

A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

US pharma giant Pfizer has announced that it is discontinuing development of danuglipron (PF-06882961), an oral glucagon-like ...

Pfizer to discontinue development of danuglipron, an oral GLP- receptor agonist for chronic weight management: New York Wednesday, April 16, 2025, 13:00 Hrs [IST] Pfizer Inc. anno ...

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...